drugset / Trial / NCT00604565
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
Terminated
11 enrolled
Charles Drew University of Medicine and Science
National Institutes of Health (NIH) · collabRockwell Medical Technologies, Inc. · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the development of iron deficiency, thereby maintaining hemoglobin level; is clinically safe and does not lead to oxidative stress or inflammation.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triferic | Other / unclassified | 96 ug | Other |
| Subject | Triferic | Other / unclassified | 95 mg | Other |